Arndt Vogel, MD

Disease characteristics and real-world treatment pathways of BRAF V600E-mutant metastatic colorectal cancer patients: Analysis of 120 patients enrolled in the BERING CRC study

BackgroundAssociated with a poor prognosis, there is an increased medical need for BRAFV600E-mutant metastatic colorectal cancer (mCRC) patients for improved therapeutic approaches. Upon ...

Arndt Vogel , MD;

06/25/2023

Atezolizumab plus bevacizumab is associated with improved survival outcomes in HCC patients with Child-Pugh B dysfunction compared to best supportive therapy

BackgroundAtezolizumab plus bevacizumab (A+B) is the recommended first line for unresectable HCC (uHCC) in patients with well-preserved liver function. Emerging evidence supports the safe...

Arndt Vogel , MD;

06/25/2023

Brightline-2: A phase IIa/IIb, open-label trial of the MDM2–p53 antagonist BI 907828 in patients with advanced MDM2-amplified, TP53 wild-type biliary tract cancer, pancreatic ductal adenocarcinoma, or other selected solid tumours

BackgroundFurther therapeutic options are urgently required for patients with biliary tract cancer (BTC), pancreatic ductal adenocarcinoma (PDAC), lung adenocarcinoma and bladder cancer, ...

Arndt Vogel , MD;

06/25/2023

An improved personalized medicine network: The PLATON from GI and beyond

BackgroundPersonalized medicine aims to treat patients individually according to their biological and molecular features by directly targeting tumor-specific markers. Gastrointestinal can...

Arndt Vogel , MD;

06/25/2023

Recruitment of gastrointestinal cancer patients via PLATON Network: An interactive precision oncology platform

BackgroundThe success of targeted therapies can be evaluated via clinical trials with a wide range of patient cohorts. On the other hand, patient enrolment is one of the main limiting fac...

Arndt Vogel , MD;

06/25/2023